Clinical utility of the modified Glasgow prognostic score in patients with advanced head and neck cancer

Head & Neck ◽  
2014 ◽  
Vol 37 (12) ◽  
pp. 1745-1749 ◽  
Author(s):  
Masahiro Nakayama ◽  
Keiji Tabuchi ◽  
Akira Hara
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Clinical Utility ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Advanced Head ◽  
Modified Glasgow Prognostic Score

scholarly journals Assessment of Cachexia in Head and Neck Cancer Patients Based on a Modified Glasgow Prognostic Score

2016 ◽  
Vol 119 (2) ◽  
pp. 125-128
Author(s):  
Takashi Matsuzuka ◽  
Masahiro Suzuki ◽  
Satoshi Saijoh ◽  
Masakazu Ikeda ◽  
Mitsumasa Imaizumi ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Modified Glasgow Prognostic Score

scholarly journals Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kiyoshi Minohara ◽  
Takuma Matoba ◽  
Daisuke Kawakita ◽  
Gaku Takano ◽  
Keisuke Oguri ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Median Overall Survival ◽  
Prognostic Score ◽  
Performance Status ◽  
Glasgow Prognostic Score ◽  
Individual Treatment ◽  
Modified Glasgow Prognostic Score ◽  
The Impact

AbstractAlthough several prognostic factors in nivolumab therapy have been reported in recurrent or metastatic head and neck cancer (RM-HNC) patients, these factors remain controversial. Here, we conducted a multicenter retrospective cohort study to investigate the impact of clinico-hematological factors on survival in RM-HNC patients treated with nivolumab. We reviewed 126 RM-HNC patients from seven institutes. We evaluated the prognostic effects of clinico-hematological factors on survival. The median overall survival (OS) was 12.3 months, and the 1 year-OS rate was 51.2%. Patients without immune-related adverse events, lower relative eosinophil count, worse best overall response, higher performance status, and higher modified Glasgow Prognostic Score had worse survival. The score, generated by combining these factors, was associated with survival. Patients with score of 4–5 had worse survival than those with score of 2–3 and 0–1 [adjusted HR for PFS: score of 4–5, 7.77 (3.98–15.15); score of 2–3, 3.44 (1.95–6.06), compared to score of 0–1], [adjusted HR for OS: score of 4–5, 14.66 (4.28–50.22); score of 2–3, 7.63 (2.29–25.37), compared to score of 0–1]. Our novel prognostic score utilizing clinico-hematological factors might be useful to establish an individual treatment strategy in RM-HNC patients treated with nivolumab therapy.

Sign in / Sign up

Export Citation Format

Share Document